InnoCare to present clinical data of Orelabrutinib at the upcoming 61st Annual Meeting of ASH

InnoCare announced that it will present clinical data on its investigational BTK inhibitor Orelabrutinib (ICP-022) at the 61st American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019 in Orlando, USA. The study in Patients with Relapsed or Refractory Mantle Cell Lymphoma, led by Dr. Jun Zhu, will be presented in an oral presentation. The study in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia, led by Dr. Jianyong Li, will be presented in poster.

Oral Presentation：

Title：Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
Abstract Number: 755
Session Name: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies
Session Date: Monday, December 9th, 2019
Session Time: 2:45 PM - 4:15 PM
Presentation Time: 3:45 PM
Location: Orange County Convention Center, Hall D
Presenter: Yuqin Song, M.D., Ph.D.

Poster Presentation：

Title：Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
Abstract Number：4319
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster III
Session Date: Monday, December 9th, 2019
Presentation Time: 6:00 PM - 8:00 PM
Location: Orange County Convention Center, Hall B
Presenter: Wei Xu, M.D.

About Orelabrutinib (ICP-022)：

Orelabrutinib is a specific and selective BTK inhibitor for the treatment of tumors and autoimmune diseases, which has been supported by the national special project for the development of major new drugs. Orelabrutinib’s been studied in multiple indications, currently in phase I/II clinical trial, with preliminary results showing promising safety and efficacy.